Swiss contract drug manufacturer Lonza said on Wednesday it would buy one of the world's largest manufacturing sites for biologic drugs in California from drugmaker Roche for $1.2 billion.

Lonza expands biologics manufacturing capacity with acquisition of Genentech facility in Vacaville, CA. $1.2 billion deal includes employee retention and facility upgrades. Transaction expected to ...

Lonza has acquired Genentech’s large-scale biologics manufacturing site in Vacaville, ... Lonza will manufacture existing products for Roche at a committed volume of 30% of capacity in 2025.

Lonza Group AG / Key word(s): Acquisition Lonza Completes Acquisition of Large-Scale Biologics Site in Vacaville (US) from Roche 01.10.2024 / 16:45 CET/CEST The Vacaville site is one of the ...

Swiss contract drug manufacturer Lonza (OTCPK:LZAGF) (OTCPK:LZAGY) has agreed to acquire a large-scale biologics manufacturing site in California from Roche (OTCQX:RHHBY) (OTCQX:RHHBF) for $1.2B ...

Lonza’s biologics segment accounted for 51% of its first half of 2021 revenue. ... Lonza manufactures products for the entirety of their commercial life, which is often around 10 years.

Lonza, the Swiss Biotech firm that purchased Vacaville’s Genentech plant from Roche in 2024, released a streamlined operating model and invitations to its Annual General Meeting in Basel ...

Thursday, KeyBanc Capital Markets increased its price target for Lonza Group (LONN:SW) (OTC: LZAGY) shares to CHF 635 from CHF 610, while keeping an Overweight rating on the stock. The adjustment ...

(Reuters) -Swiss contract drug manufacturer Lonza said on Wednesday it would buy one of the world's largest manufacturing sites for biologic drugs in California from drugmaker Roche for $1.2 billion.

Lonza plans to invest approximately CHF 500 million to further upgrade the facility and add capabilities to meet demand for the next generation of mammalian biologics therapies. The products ...

Lonza, announced it has completed its acquisition of the Genentech large-scale biologics manufacturing site in Vacaville, California (US) from Roche for USD 1.2 billion. The Vacaville facility ...

Swiss contract drug manufacturer Lonza said on Wednesday (Mar 20) it signed an agreement to acquire the Genentech manufacturing facility in Vacaville, California, from drugmaker Roche for US$1.2 ...